AC-055-402: An Extension of AC-055-401, a Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument
Phase of Trial: Phase III
Latest Information Update: 28 Aug 2018
Price : $35 *
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms SYMPHONYext
- Sponsors Actelion Pharmaceuticals
- 08 Jun 2016 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016.
- 01 Mar 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 17 May 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.